BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1301 related articles for article (PubMed ID: 16420035)

  • 1. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
    Puntambekar DS; Giridhar R; Yadav MR
    Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
    Bhongade BA; Gouripur VV; Gadad AK
    Bioorg Med Chem; 2005 Apr; 13(8):2773-82. PubMed ID: 15781388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
    Bhongade BA; Gadad AK
    Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
    Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
    J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues.
    Juvale DC; Kulkarni VV; Deokar HS; Wagh NK; Padhye SB; Kulkarni VM
    Org Biomol Chem; 2006 Aug; 4(15):2858-68. PubMed ID: 16855733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme.
    Adane L; Bharatam PV
    J Mol Graph Model; 2009 Nov; 28(4):357-67. PubMed ID: 19796975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CoMFA and CoMSIA studies on thiazolidin-4-one as anti-HIV-1 agents.
    Murugesan V; Prabhakar YS; Katti SB
    J Mol Graph Model; 2009 Feb; 27(6):735-43. PubMed ID: 19117780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
    da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
    Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
    Puntambekar D; Giridhar R; Yadav MR
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
    Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
    Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D QSAR studies of 1,3,4-benzotriazepine derivatives as CCK2 receptor antagonists.
    Kaur K; Talele TT
    J Mol Graph Model; 2008 Nov; 27(4):409-20. PubMed ID: 18774323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-dimensional quantitative structure: activity relationship studies on diverse structural classes of HIV-1 integrase inhibitors using CoMFA and CoMSIA.
    Nunthaboot N; Tonmunphean S; Parasuk V; Wolschann P; Kokpol S
    Eur J Med Chem; 2006 Dec; 41(12):1359-72. PubMed ID: 17002889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-QSAR analysis of human immunodeficiency virus entry-1 inhibitors by CoMFA and CoMSIA.
    Pirhadi S; Ghasemi JB
    Eur J Med Chem; 2010 Nov; 45(11):4897-903. PubMed ID: 20810190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
    Puntambekar DS; Giridhar R; Yadav MR
    Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods.
    Zhu YQ; Pei JF; Liu ZM; Lai LH; Cui JR; Li RT
    Bioorg Med Chem; 2006 Mar; 14(5):1483-96. PubMed ID: 16256351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An investigation of structurally diverse carbamates for acetylcholinesterase (AChE) inhibition using 3D-QSAR analysis.
    Roy KK; Dixit A; Saxena AK
    J Mol Graph Model; 2008 Sep; 27(2):197-208. PubMed ID: 18515163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.